* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Molecular Degrader of Extracellular proteins through the Asialoglycoprotein receptor (MoDE-A) is a class of modular, bifunctional synthetic molecules developed for targeted protein degradation (TPD) of extracellular and membrane-associated proteins. In simple terms, MoDE-A works like a molecular bridge outside the cell. One end binds the extracellular target protein, while the other end engages the asialoglycoprotein receptor (ASGPR), a receptor highly expressed on hepatocytes. After the target protein is connected to ASGPR, the target–MoDE-A–ASGPR complex can be internalized into the cell, transported through the endosome–lysosome pathway, and broken down by lysosomal enzymes.
MoDE-A is different from a traditional proteolysis targeting chimera (PROTAC). Conventional PROTACs usually act inside cells by recruiting an E3 ubiquitin ligase, inducing ubiquitination, and directing the protein of interest (POI) to the proteasome. MoDE-A does not rely on E3 ligase-mediated ubiquitination or proteasomal degradation. Instead, it uses an “outside-in” lysosomal degradation route to clear extracellular or membrane-associated proteins. This makes MoDE-A especially valuable for targets that are difficult to address with intracellular degradation strategies, such as circulating antibodies, secreted disease mediators, pro-inflammatory cytokines, soluble receptors, and selected cell-surface proteins.
BOC Sciences provides integrated MoDE-A technology development services for pharmaceutical, biotechnology, and research organizations seeking to explore ASGPR-mediated extracellular protein degradation. Our support covers target feasibility assessment, target-binding warhead strategy, ASGPR-binding ligand design, linker optimization, MoDE-A molecule synthesis, binding validation, endocytosis assessment, lysosomal degradation profiling, selectivity evaluation, and iterative structure–degradation relationship analysis. By integrating medicinal chemistry, extracellular protein biology, lysosomal degradation knowledge, and degradation-focused assay design, we help clients convert early MoDE-A concepts into experimentally testable and optimization-ready degrader candidates.
Services
BOC Sciences' Comprehensive MoDE-A Technology Development Services
Extracellular Target Feasibility Assessment
A successful MoDE-A project begins with determining whether the selected extracellular or membrane-associated protein can be productively captured, internalized, and degraded through an ASGPR-mediated lysosomal pathway. We evaluate target abundance, extracellular accessibility, binding epitope exposure, soluble versus membrane-associated state, disease-pathway relevance, assay feasibility, and availability of target-binding molecules to define a realistic project path.
Assessment of extracellular target accessibility and biological relevance
Review of soluble, circulating, secreted, or membrane-associated target format
Identification of target-binding, endocytosis, and lysosomal readout requirements
Target-Binding Warhead Strategy
The target-binding warhead determines whether a MoDE-A molecule can selectively recognize the extracellular protein under biologically relevant conditions. BOC Sciences supports warhead selection, binder-format comparison, affinity assessment, epitope suitability analysis, and conjugation-position planning to help clients build a target-engagement module that is compatible with ASGPR-mediated internalization.
Evaluation of small-molecule, peptide, antibody-derived, or aptamer-like binding strategies
Binding epitope and accessibility analysis for extracellular target engagement
Warhead derivatization planning for bifunctional MoDE-A assembly
ASGPR-Binding Ligand Design
ASGPR engagement is the central feature of MoDE-A technology. We help clients design and optimize ASGPR-binding modules that can recruit hepatocyte ASGPR efficiently while maintaining compatibility with the target-binding warhead and linker. Our design considerations include receptor-binding motif selection, multivalent presentation, spacing, steric compatibility, and cellular uptake behavior.
ASGPR-binding ligand selection and structural optimization
Design of GalNAc-inspired or related ASGPR-recognition motifs
Receptor engagement assessment and uptake-oriented design
The linker in a MoDE-A molecule is not only a spacer; it controls whether the extracellular target and ASGPR can be brought into a productive geometry for receptor-mediated endocytosis. We optimize linker length, flexibility, polarity, attachment site, branching pattern, and steric distance to improve target bridging, cellular uptake, and lysosomal delivery.
PEG, alkyl, rigid, heterocyclic, and branched linker design strategies
Attachment-site evaluation on target-binding and ASGPR-binding modules
Structure–degradation relationship analysis across linker variants
MoDE-A Synthesis and Analog Expansion
BOC Sciences supports custom synthesis of MoDE-A molecules from early design to focused analog libraries. We prepare target-binding module intermediates, ASGPR-binding module intermediates, linker-modified conjugates, and complete bifunctional degraders, enabling clients to compare multiple molecular designs and identify structures with stronger extracellular protein clearance potential.
Custom synthesis of MoDE-A candidates and analog series
Modular conjugation route exploration and synthetic feasibility assessment
Chemistry optimization based on binding, uptake, degradation, and cellular data
Target–MoDE-A–ASGPR Complex Validation
Formation of a productive target–MoDE-A–ASGPR complex is essential for receptor-mediated internalization. We support binding affinity measurement, receptor engagement assays, ternary complex evaluation, competition studies, and concentration-response analysis to determine whether the MoDE-A candidate can bridge the extracellular target and ASGPR effectively.
Competition and blocking studies for mechanism confirmation
Troubleshooting of weak bridging, hook effect, or nonproductive binding behavior
Endocytosis and Lysosomal Trafficking Evaluation
MoDE-A activity depends on ASGPR-mediated internalization and delivery to lysosomes. We design cellular evaluation workflows to monitor target uptake, endosomal trafficking, lysosomal colocalization, receptor recycling behavior, and time-dependent target reduction. These studies help clarify whether target clearance is driven by the intended ASGPR–lysosome pathway.
Cellular uptake and receptor-mediated endocytosis assessment
Lysosomal colocalization and trafficking analysis
Time-course evaluation of target internalization and degradation
Mechanistic validation using pathway-modulation and competition controls
MoDE-A In Vitro and Cell-Based Degradation Profiling
We provide integrated assays to quantify extracellular target depletion, cellular uptake, lysosomal degradation efficiency, selectivity, and functional consequences in relevant cell models. The resulting data help clients prioritize MoDE-A candidates based not only on target binding, but also on true ASGPR-mediated clearance and degradation behavior.
Target depletion analysis using immunoassay, Western blot, or fluorescence-based readouts
MoDE-A development requires coordinated decisions across extracellular target selection, target-binding warhead design, ASGPR ligand strategy, linker architecture, receptor-mediated endocytosis assays, lysosomal degradation validation, and data interpretation. BOC Sciences provides integrated solutions that connect molecular design with functional target clearance, helping clients make confident decisions at each stage of the program.
Solution for Extracellular Target Feasibility
A common challenge is that a protein may be biologically attractive but not readily accessible for ASGPR-mediated uptake. To address this, we evaluate whether the target exists as a soluble, secreted, circulating, or membrane-associated protein; whether its binding epitope remains exposed; and whether target abundance and turnover support measurable depletion. This feasibility-first strategy helps clients avoid poorly matched targets and focus resources on MoDE-A programs with realistic degradation potential.
Solution for Warhead and ASGPR Module Compatibility
MoDE-A molecules must bind both the extracellular target and ASGPR without creating steric conflict or nonproductive orientation. We compare target-binding formats, assess conjugation tolerance, evaluate ASGPR-binding motifs, and design module combinations that support simultaneous engagement. This approach helps improve target–degrader–receptor complex formation and reduces the risk that strong binary binding fails to translate into cellular uptake.
Solution for Linker Geometry and Endocytosis Efficiency
The linker must position the extracellular target near ASGPR in a geometry that supports receptor-mediated internalization. We design structured linker sets that vary length, flexibility, polarity, branching, and attachment orientation. By correlating these structures with uptake, lysosomal colocalization, and degradation readouts, we identify linker patterns that improve target clearance rather than simply increasing molecular size or binding avidity.
Solution for Lysosomal Mechanism Confirmation
Apparent target loss can result from assay interference, target masking, nonspecific uptake, or cellular stress rather than true lysosomal degradation. Our validation workflow integrates dose-response studies, time-course profiling, ASGPR competition, lysosomal trafficking analysis, target recovery assessment, and pathway-modulation controls. This allows clients to determine whether observed target depletion is consistent with the intended MoDE-A mechanism.
Choose BOC Sciences to Build More Reliable MoDE-A Degradation Programs!
From extracellular target feasibility and ASGPR ligand strategy to linker optimization, custom MoDE-A synthesis, endocytosis assessment, lysosomal degradation assays, and iterative analog optimization, BOC Sciences provides tailored support for ASGPR-mediated extracellular protein degradation projects. Our interdisciplinary expertise helps clients reduce design uncertainty, generate decision-ready data, and advance promising MoDE-A candidates with greater confidence.
Our MoDE-A Solutions Support Diverse R&D Organizations
Research Institutes and Academic Laboratories
Academic teams often use MoDE-A technology to explore extracellular protein clearance, receptor-mediated lysosomal degradation, and the biological consequences of removing soluble or membrane-associated targets. We support these projects with flexible design, synthesis, binding, uptake, and degradation assay modules that help generate reliable mechanistic research data.
Biotechnology Companies
Biotechnology companies may need rapid proof-of-concept data to determine whether ASGPR-mediated degradation can support a new extracellular target program. BOC Sciences helps accelerate early decision-making through target assessment, modular MoDE-A design, focused analog synthesis, cellular uptake analysis, and lysosomal degradation profiling.
Pharmaceutical Discovery Teams
Pharmaceutical discovery teams can use MoDE-A technology to evaluate extracellular and membrane-associated targets that are not suitable for intracellular PROTAC strategies. We provide systematic support for target-binding module selection, ASGPR engagement, linker optimization, target depletion assays, selectivity analysis, and mechanism-focused validation.
CROs / Technical Service Platforms
CROs and technical platforms may require specialized MoDE-A expertise to complement internal chemistry or biology capabilities. We offer modular cooperation models covering warhead evaluation, ASGPR ligand design, linker optimization, bifunctional molecule synthesis, endocytosis assay development, lysosomal degradation validation, and data interpretation.
Understand the client's extracellular target, available binding molecules, target format, biological context, desired degradation readouts, preferred cell models, and project-stage objectives.
02
Target Feasibility and MoDE-A Strategy Assessment
Evaluate extracellular accessibility, target-binding feasibility, ASGPR-mediated uptake suitability, assay availability, and potential technical risks to define a practical development route.
03
Proposal Design, Scope Definition, and Quotation
Prepare a tailored research plan covering design scope, synthesis scale, analog number, binding assays, uptake assays, degradation package, data output, and decision points.
04
Project Initiation and Technical Data Transfer
Receive target information, binder structures, protein samples, assay protocols, reference molecules, cell model information, and project background materials required for efficient execution.
05
MoDE-A Molecule Design and Synthesis Initiation
Design and synthesize MoDE-A molecules by combining target-binding warheads, ASGPR-binding ligands, and optimized linker architectures across focused molecular series.
06
Binding, Uptake, and Lysosomal Degradation Validation
Evaluate target binding, ASGPR engagement, ternary complex formation, receptor-mediated endocytosis, lysosomal trafficking, and target depletion in relevant cellular systems.
07
Optimization Iteration and Selectivity Assessment
Refine warhead, ASGPR ligand, linker, and molecular architecture based on binding affinity, uptake efficiency, Dmax, degradation kinetics, and selectivity data.
08
Molecule Delivery and Data Reporting
Deliver molecular samples, experimental data, binding and degradation profiles, structure–degradation relationship interpretation, and clear recommendations for the next design or validation cycle.
Advantages
Advantages of MoDE-A Technology
Targets Extracellular Proteins
MoDE-A expands targeted protein degradation beyond intracellular proteins by enabling clearance of extracellular, circulating, secreted, and selected membrane-associated targets through ASGPR-mediated uptake.
Uses Lysosomal Degradation
Instead of recruiting E3 ubiquitin ligases and the proteasome, MoDE-A takes advantage of receptor-mediated endocytosis and lysosomal proteolysis to remove proteins located outside the cell.
Modular Bifunctional Design
The target-binding warhead, ASGPR-binding ligand, and linker can be optimized independently and then integrated to improve binding, target bridging, uptake, and degradation performance.
Complements PROTAC Strategies
For targets inaccessible to intracellular PROTACs, MoDE-A provides an alternative degradation route and can be compared with PROTAC degradation technology development programs.
Applications
Applications Supported by Our MoDE-A Technology Platform
Extracellular Protein Clearance
Design of MoDE-A molecules for soluble or circulating protein targets
Degradation studies for secreted disease mediators and extracellular signaling proteins
Evaluation of target depletion using hepatocyte-relevant cellular systems
Support for ASGPR-mediated uptake and lysosomal clearance research
Cytokine and Immune Mediator Research
MoDE-A development for pro-inflammatory cytokines and soluble immune-related proteins
Target-binding warhead selection for extracellular immune mediators
Degradation profiling under relevant cellular and protein-abundance conditions
Data-driven prioritization of degrader modality and molecular design direction
Case Study
Client Success Stories: MoDE-A Technology Development
Project Background
A biotechnology research team wanted to evaluate whether a soluble pro-inflammatory cytokine could be depleted using an ASGPR-mediated MoDE-A strategy. The client had a peptide-derived target-binding motif with moderate affinity but did not know whether conjugation to an ASGPR-binding module would preserve target recognition, support receptor engagement, and drive measurable lysosomal degradation.
Our Support
We first assessed the cytokine-binding motif and identified two derivatization positions that were less likely to interfere with target engagement. Based on these attachment sites, we designed 24 MoDE-A candidates combining a target-binding warhead, ASGPR-binding motifs with different valency patterns, and PEG-based or semi-rigid linkers ranging from short to extended spacing. Initial binding assays showed that several highly flexible linkers preserved target affinity but produced weak receptor-mediated uptake. We then prioritized a mid-length PEG-linked series with improved target–MoDE-A–ASGPR bridging. In hepatocyte-relevant cellular assays, the optimized candidate showed time-dependent target depletion, lysosomal colocalization, and reduced target level under conditions where competition with an excess ASGPR ligand weakened the effect. The best analog provided the client with a clear molecular template for further optimization.
Client Testimonial
BOC Sciences helped us understand why target binding alone was not sufficient for extracellular protein degradation. Their MoDE-A workflow connected ASGPR engagement, linker geometry, uptake, and lysosomal readouts into a practical optimization plan.
Project Background
A discovery team wanted to explore MoDE-A-mediated clearance of a membrane-associated protein with an extracellular domain. Early bifunctional designs showed target binding but inconsistent reduction of surface protein levels. The client needed support to redesign the molecular architecture, confirm whether ASGPR engagement was productive, and generate interpretable cellular degradation data.
Our Support
We reviewed the extracellular epitope, binder orientation, and proposed conjugation site, then found that the original linker likely positioned the ASGPR-binding motif too close to the cell-surface target, creating steric limitations for productive internalization. We designed 18 new MoDE-A analogs using two target-warhead attachment sites, three linker families, and two ASGPR-binding presentation patterns. Screening across 4 h, 12 h, and 24 h treatment windows showed that a short rigid linker retained surface binding but gave limited internalization. A second design round introduced a longer semi-flexible linker, which improved target internalization and lysosomal trafficking. The optimized candidate produced reproducible reduction of the membrane-associated target and gave the client a defined structure–degradation relationship for the next analog cycle.
Client Testimonial
The BOC Sciences team did more than synthesize molecules. They helped us identify the spatial problem in our early MoDE-A designs and turned the project into a data-driven extracellular degradation campaign.
Why Us
Why Choose BOC Sciences for Your MoDE-A Project?
Integrated MoDE-A Development Support
We provide coordinated support across extracellular target assessment, warhead strategy, ASGPR ligand design, linker optimization, synthesis, cellular uptake assays, and degradation profiling.
Expertise in ASGPR-Mediated Degradation
Our team understands the unique design logic of MoDE-A molecules, including target accessibility, ASGPR recruitment, endocytosis, lysosomal trafficking, and extracellular target clearance.
Flexible Modular Service Models
Clients can access single-service support, such as linker design or uptake assay development, or request end-to-end MoDE-A development from concept to optimized candidate series.
Mechanism-Focused Validation
Our validation workflows help determine whether target depletion is consistent with ASGPR-mediated endocytosis and lysosomal degradation rather than nonspecific binding or assay artifacts.
Data-Driven Design Iteration
We connect chemistry and biology data to refine target-binding warheads, ASGPR-binding ligands, linker architecture, cellular assay conditions, and degradation readouts.
Clear Reporting and Decision Support
We provide organized experimental data, practical interpretation, and clear recommendations to support the next stage of MoDE-A design, screening, or optimization.
MoDE-A (Molecular Degraders of Extracellular proteins via the asialoglycoprotein receptor, ASGPR) is a novel bifunctional strategy designed to selectively degrade extracellular or membrane-associated proteins. It works by linking the protein of interest (POI) to ASGPR on hepatocytes, inducing receptor-mediated endocytosis, and directing the protein to the lysosome for degradation. This approach enables modulation of proteins inaccessible to intracellular degradation systems and expands the range of therapeutic targets.
Which proteins are suitable targets for MoDE-A degradation?
MoDE-A technology is most effective for extracellular proteins, secreted factors, or membrane proteins with exposed domains suitable for ASGPR engagement. Target selection involves evaluating expression levels, accessibility, disease relevance, and ligand availability. By performing feasibility studies, BOC Sciences helps clients identify suitable POIs that can be efficiently internalized and degraded, ensuring the initial design and experimental resources are strategically directed toward high-probability success candidates.
How are MoDE-A molecules designed and optimized?
MoDE-A molecule design combines a POI-binding ligand, an ASGPR-recruiting motif, and an optimized linker. Critical design considerations include binding affinity, steric compatibility, linker length, flexibility, polarity, and cellular accessibility. Iterative optimization involves synthesizing focused analog series, measuring endocytosis efficiency, monitoring lysosomal trafficking, and evaluating degradation kinetics. This structured approach ensures molecules achieve maximal target clearance while maintaining favorable physicochemical properties and minimizing off-target effects.
Can MoDE-A technology be integrated with other therapeutic modalities?
Yes, MoDE-A technology can complement conventional antibody therapies, small-molecule inhibitors, or other targeted protein degradation strategies. By combining MoDE-A with intracellular degrader systems like PROTACs or SNIPERs, researchers can target both extracellular and intracellular pools of disease-relevant proteins. Comparative studies allow optimization of degradation efficacy, tissue specificity, and therapeutic index, enabling flexible design strategies that maximize biological insight and accelerate translational research outcomes.
How does BOC Sciences support MoDE-A development?
BOC Sciences provides end-to-end MoDE-A development services, including target feasibility evaluation, POI ligand design, ASGPR motif selection, linker optimization, custom molecule synthesis, cellular internalization and lysosomal degradation assays, mechanistic validation, and structure-activity relationship (SAR) guided optimization. This integrated workflow generates interpretable data, ensures reliable protein degradation, and helps clients make informed decisions to advance promising MoDE-A candidate molecules efficiently from concept to experimental validation.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Targets Extracellular Proteins
